| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a276b0dd2986c6afefd0fe0104e60ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e19ed5092514d4f22acfa3bc98b8b572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7391d86620a46228a99e8ab09d7c7cea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_943d0646c28c3b83ee3454f9714b11c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966480af70de9ec89a21b5035d89da34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e799cb21af9a431a037eb6e9a5456477 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate |
2005-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9214830efb316434991cf284e07bce4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391ca8c2aa782d6af78da6c05a44fd78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6db2388c1c58d74fb5c767759ed8ae70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e2468e3df8a1e06291ef7ac1af4e40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff8c519b3e4d8b138f0ee733adb3ba8d |
| publicationDate |
2005-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005096692-A2 |
| titleOfInvention |
Crystalline forms of mizolastine, production methods thereof and pharmaceutical compositions containing same |
| abstract |
The invention relates to a crystalline form mizolastine which is substantially free of water and solvent and which is known as Form A and another crystalline form of mizolastine which is substantially free of solvent and which is known as Form B, said two forms being characterised by infrared spectroscopy, differential scanning calorimetry and X-ray powder diffraction. The aforementioned crystalline forms can be obtained by means of recrystallisation of mizolastine in an organic solvent in the presence or absence of water. The pharmaceutical compositions containing said crystalline forms can be used for the treatment of allergic disorders. |
| priorityDate |
2004-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |